Thursday, 5 December 2013

New data support flexibility in timing of administration for Sanofi's lixisenatide

The results of a 24-week Phase IIIb clinical study showed that lixisenatide met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or the main meal of the day. These results indicate that lixisenatide can effectively lower blood sugar at either time of administration (Sanofi)

No comments:

Post a Comment